100 related articles for article (PubMed ID: 10340914)
1. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
de Jonge MJ; Verweij J; Loos WJ; Dallaire BK; Sparreboom A
Clin Pharmacol Ther; 1999 May; 65(5):491-9. PubMed ID: 10340914
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Sparreboom A; de Jonge MJ; Punt CJ; Nooter K; Loos WJ; Porro MG; Verweij J
Clin Cancer Res; 1998 Aug; 4(8):1915-9. PubMed ID: 9717819
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.
Xiong HQ; Tran HT; Madden TL; Newman RA; Abbruzzese JL
Clin Cancer Res; 2003 Jun; 9(6):2066-71. PubMed ID: 12796369
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
7. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
[TBL] [Abstract][Full Text] [Related]
9. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
Takimoto CH; Dahut W; Marino MT; Nakashima H; Liang MD; Harold N; Lieberman R; Arbuck SG; Band RA; Chen AP; Hamilton JM; Cantilena LR; Allegra CJ; Grem JL
J Clin Oncol; 1997 Apr; 15(4):1492-501. PubMed ID: 9193345
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
[TBL] [Abstract][Full Text] [Related]
12. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
[TBL] [Abstract][Full Text] [Related]
14. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Sparreboom A; de Jonge MJ; Punt CJ; Loos WJ; Nooter K; Stoter G; Porro MG; Verweij J
Drug Metab Dispos; 1999 Jul; 27(7):816-20. PubMed ID: 10383926
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
de Jonge MJ; Punt CJ; Gelderblom AH; Loos WJ; van Beurden V; Planting AS; van der Burg ME; van Maanen LW; Dallaire BK; Verweij J; Wagener DJ; Sparreboom A
J Clin Oncol; 1999 Jul; 17(7):2219-26. PubMed ID: 10561279
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
Frapolli R; Zucchetti M; Sessa C; Marsoni S; Viganò L; Locatelli A; Rulli E; Compagnoni A; Bello E; Pisano C; Carminati P; D'Incalci M
Eur J Cancer; 2010 Feb; 46(3):505-16. PubMed ID: 20007015
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Mani S; Iyer L; Janisch L; Wang X; Fleming GF; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42(1):84-7. PubMed ID: 9619763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
